Chris Fox – General Manager, Amgen UK & Ireland
Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America,…
Address: 1 Royal College St ,London, Greater London NW1 0SB, UK
Tel: +44(0) 20 7691 4906
Web: http://www.xeneticbio.com/
Xenetic is a leading UK based biopharmaceutical company providing leading edge expertise in the development of a whole new generation of drugs and vaccines.
Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas.
We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen andImuXen platform technologies.
Xenetic’s biopharmaceutical pipeline contains a range of product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners. The products in Xenetic’s pipeline have a multi-billion dollar market potential.
Pipeline products are based on Xenetic’s proprietary drug and vaccine delivery technologies and have been developed to offer improved performance and delivery characteristics. Xenetic’s unique delivery technologies are also able to create new high-value, differentiated proprietary products from off-patent actives.
Xenetic has established a range of partnerships with major US, European, Russian and Asian biotechnology and pharmaceutical companies to develop new protein therapeutics and vaccines. Click here to learn more about the work we do with our partners.
Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America,…
Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He…
Jeremy Thorpe established Tillotts Pharma’s operations in the UK, building his team around the central pillar of customer relationships. Jeremy explains how his company’s approach allowed it to reach £25…
Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric…
Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the…
With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE,…
Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the…
Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on…
Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential…
Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences…
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
Ian Shott, co-founder and CEO of Arcinova, tells the story of how he established a speciality CMO on an historic site and discloses his plans to revolutionise small molecule manufacturing…
See our Cookie Privacy Policy Here